Medanta Q1 FY27 Total Income Rises 26.2% YoY to ₹13,262 Million
Global Health Limited reported record Q1 FY27 consolidated total income of ₹13,262 million, up 26.2% YoY. EBITDA grew 23.5% to ₹3,153 million. Patient volumes increased significantly. The company added 72 beds and plans to add 2,950 beds across five greenfield projects, including a 650-bed hospital in Guwahati.
The announcement details significant revenue growth, operational expansion, and strategic future investments, which are material factors for investors and stakeholders.
The company reported record quarterly income and EBITDA with strong year-on-year growth, driven by increased patient volumes and capacity expansion, indicating a positive financial performance.
Global Health Limited (Medanta) announced its unaudited consolidated financial results for the quarter ending June 30, 2026. The company reported a record quarterly total income of ₹13,262 million, marking a significant year-on-year growth of 26.2%. EBITDA also saw a substantial increase of 23.5% year-on-year, reaching ₹3,153 million. The operational performance was driven by robust patient volume growth, with inpatient numbers increasing by 27.7% and outpatient numbers by 34.5% year-on-year.
During the quarter, Medanta added 72 new operational beds across its network, with 51 beds in Noida and 21 in Lucknow. The Noida hospital, which has been a focus area, showed improved performance with a reduced EBITDA loss of ₹49 million compared to ₹236 million in the previous quarter. The company also highlighted strong growth in its OPD Pharmacy business, with revenue increasing by 50.9% year-on-year.
Looking ahead, Medanta is expanding its network with plans for a new 80-bed cancer facility in Indore and a scaled-up 650-bed super specialty hospital in Guwahati. These greenfield projects aim to add a total of 2,950 beds over the next few years, underscoring the company's commitment to disciplined, quality-anchored growth.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.